What is Desentum?
Founded in 2011, Desentum operates at the intersection of immunology and biotechnology, focusing on the development of novel therapeutic solutions for allergic diseases. The company's core technology platform centers on re-engineering the immune system's response to allergens, effectively shifting the body from a state of hypersensitivity to one of tolerance. This mechanism represents a significant departure from traditional symptom-management approaches, positioning Desentum as a key player in the precision medicine landscape. With a history of recognition, including the prestigious EARTO Innovation Prize, the firm leverages its deep research roots to navigate the complex regulatory and clinical pathways required for bringing next-generation immunotherapies to market.
How much funding has Desentum raised?
Desentum has raised a total of $15.5M across 3 funding rounds:
Series A
$2M
Other Financing Round
$4.5M
Unspecified
$9M
Series A (2017): $2M, investors not publicly disclosed
Other Financing Round (2019): $4.5M, investors not publicly disclosed
Unspecified (2022): $9M supported by Springvest Oyj
Key Investors in Desentum
Springvest Oyj
A Finnish investment firm specializing in growth-stage financing and supporting innovative companies through public and private capital markets.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Desentum?
With the recent infusion of capital, Desentum is well-positioned to accelerate its clinical development programs and expand its operational footprint. The strategic focus will likely remain on the execution of rigorous human clinical trials, a critical milestone for validating the efficacy and safety of its hypoallergen-based treatments. As the company scales, it will likely prioritize the commercialization of its intellectual property and the strengthening of its strategic partnerships within the global pharmaceutical ecosystem. The current funding trajectory suggests a transition toward late-stage development, where the company must demonstrate sustained therapeutic impact to secure its long-term market viability and address the unmet needs of the global allergy patient population.
See full Desentum company page
